Market Overview

UPDATE: JP Morgan Raises PT to $31 on Pfizer Following Q4 Results, Guidance

Share:
Related PFE
The Generic Drug Battle
BoA Adds Pfizer To US 1 List; It 'Won't Keep You Up At Night'
Income Investors: Are You Prepared To Ride Out The Remainder Of This Storm? (Seeking Alpha)

JP Morgan maintained Pfizer, Inc. (NYSE: PFE) with an Overweight and raised the price target from $29.00 to $31.00.

JP Morgan said, "While there were no major surprises in the guidance, management did confirm that they expect share repurchase to reach mid-teens billions of dollars range this year. More importantly, management's comments on the call reinforced our view that a larger split-up of the company remains a real possibility longer-term, something we believe would be a clear upside event for Pfizer shares. Despite the move the stock has had, we continue to see a number of drivers for further upside ranging from new product flow, to additional capital return and accretive bolt-on acquisitions."

Pfizer closed at $27.70 on Tuesday.

Latest Ratings for PFE

DateFirmActionFromTo
Feb 2016Argus ResearchMaintainsBuy
Jan 2016JefferiesMaintainsBuy
Dec 2015Atlantic EquitiesInitiates Coverage onOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: JP MorganAnalyst Color Price Target Analyst Ratings

 

Related Articles (PFE)

Get Benzinga's Newsletters